Swedish biotech firm gets green light to take diabetes candidate to clinical phase

Atrogi is starting clinical studies of its type 2 diabetes candidate, ATR-258, in Germany.
Atrogi CEO Alexandra Ekman Ryding | Photo: Atrogi /PR
Atrogi CEO Alexandra Ekman Ryding | Photo: Atrogi /PR
by christian bundgaard, translated by catherine brett

Atrogi, a biotech firm based in Sweden, is entering the clinical phase with its new class of molecules for the treatment of type 2 diabetes.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading